JP2022511813A5 - - Google Patents
Info
- Publication number
- JP2022511813A5 JP2022511813A5 JP2021531301A JP2021531301A JP2022511813A5 JP 2022511813 A5 JP2022511813 A5 JP 2022511813A5 JP 2021531301 A JP2021531301 A JP 2021531301A JP 2021531301 A JP2021531301 A JP 2021531301A JP 2022511813 A5 JP2022511813 A5 JP 2022511813A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- amino acid
- binding molecule
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025005656A JP2025063198A (ja) | 2018-12-04 | 2025-01-15 | Ｃｄ３に対する結合分子及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/119074 | 2018-12-04 | ||
| CN2018119074 | 2018-12-04 | ||
| PCT/CN2019/122876 WO2020052692A2 (en) | 2018-12-04 | 2019-12-04 | Binding molecules against cd3 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005656A Division JP2025063198A (ja) | 2018-12-04 | 2025-01-15 | Ｃｄ３に対する結合分子及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511813A JP2022511813A (ja) | 2022-02-01 |
| JP2022511813A5 true JP2022511813A5 (https=) | 2022-12-12 |
| JP7621948B2 JP7621948B2 (ja) | 2025-01-27 |
Family
ID=69778639
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531301A Active JP7621948B2 (ja) | 2018-12-04 | 2019-12-04 | Ｃｄ３に対する結合分子及びその使用 |
| JP2025005656A Pending JP2025063198A (ja) | 2018-12-04 | 2025-01-15 | Ｃｄ３に対する結合分子及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005656A Pending JP2025063198A (ja) | 2018-12-04 | 2025-01-15 | Ｃｄ３に対する結合分子及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230037682A1 (https=) |
| EP (1) | EP3891181A4 (https=) |
| JP (2) | JP7621948B2 (https=) |
| KR (1) | KR20210099614A (https=) |
| CN (1) | CN113396161A (https=) |
| AU (1) | AU2019339582A1 (https=) |
| CA (1) | CA3121842A1 (https=) |
| IL (1) | IL283635A (https=) |
| WO (1) | WO2020052692A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019195535A1 (en) * | 2018-04-05 | 2019-10-10 | Novartis Ag | Trispecific binding molecules against cancers and uses thereof |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| US12037378B2 (en) | 2019-05-21 | 2024-07-16 | Novartis Ag | Variant CD58 domains and uses thereof |
| US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
| US20230128499A1 (en) * | 2020-03-27 | 2023-04-27 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune diseases |
| WO2021231969A1 (en) * | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies |
| CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| CR20230229A (es) * | 2020-11-06 | 2023-09-05 | Amgen Res Munich Gmbh | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN113861285B (zh) * | 2021-09-15 | 2023-03-10 | 中国科学院微生物研究所 | 一种痘病毒人源单克隆抗体及其应用 |
| AU2022373303A1 (en) * | 2021-10-20 | 2024-05-09 | Memorial Hospital For Cancer And Allied Diseases | Anti-tshr multi-specific antibodies and uses thereof |
| EP4522651A1 (en) * | 2022-05-12 | 2025-03-19 | Amgen Research (Munich) GmbH | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
| CN119365212A (zh) * | 2022-06-24 | 2025-01-24 | 四川科伦药物研究院有限公司 | 特异性结合gpc3的嵌合抗原受体及其应用 |
| AU2023312397A1 (en) | 2022-07-29 | 2025-03-13 | Zymeworks Bc Inc. | Multivalent and bispecific antibody constructs and methods of use thereof |
| EP4619038A2 (en) * | 2022-11-14 | 2025-09-24 | Cornell University | Anionically functionalized polypeptides, and methods of making same and uses thereof |
| AU2024341660A1 (en) * | 2023-09-11 | 2026-03-12 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof |
| WO2025119253A1 (en) * | 2023-12-06 | 2025-06-12 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel antibodies that bind to cd3 and lilrb4, and uses thereof |
| WO2025255480A1 (en) * | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06004035A (es) | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| RU2547595C2 (ru) * | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Антитела против ccr2 |
| KR102060389B1 (ko) * | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| ME03675B (me) * | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| RU2016132863A (ru) * | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| MX375669B (es) * | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2018178047A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
-
2019
- 2019-12-04 WO PCT/CN2019/122876 patent/WO2020052692A2/en not_active Ceased
- 2019-12-04 AU AU2019339582A patent/AU2019339582A1/en not_active Abandoned
- 2019-12-04 JP JP2021531301A patent/JP7621948B2/ja active Active
- 2019-12-04 US US17/311,315 patent/US20230037682A1/en active Pending
- 2019-12-04 CN CN201980090683.5A patent/CN113396161A/zh active Pending
- 2019-12-04 CA CA3121842A patent/CA3121842A1/en active Pending
- 2019-12-04 KR KR1020217020420A patent/KR20210099614A/ko not_active Withdrawn
- 2019-12-04 EP EP19859601.7A patent/EP3891181A4/en active Pending
-
2021
- 2021-06-01 IL IL283635A patent/IL283635A/en unknown
-
2025
- 2025-01-15 JP JP2025005656A patent/JP2025063198A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511813A5 (https=) | ||
| JP2021503892A5 (https=) | ||
| RU2020120411A (ru) | Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP2022031784A5 (https=) | ||
| JP2022510218A5 (https=) | ||
| JP2023519974A5 (https=) | ||
| JP2025078629A5 (https=) | ||
| US20160000842A1 (en) | Oncolytic virus | |
| JP2022548796A5 (https=) | ||
| JP2021502104A5 (https=) | ||
| JP2020531525A5 (https=) | ||
| IL312224B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CN115698088A (zh) | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 | |
| BR112019017629A2 (pt) | receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor | |
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| HRP20250135T1 (hr) | Notch receptori sa zglobnom domenom | |
| WO2022222910A1 (zh) | 靶向gprc5d的抗体及其用途 | |
| WO2016055592A1 (en) | Bispecific antibodies against cd3epsilon and ror1 | |
| JP2024532482A5 (https=) | ||
| WO2021058807A1 (en) | Trivalent binding molecules | |
| JP2021513961A5 (https=) | ||
| JP2021534769A5 (https=) | ||
| JP2023549555A5 (https=) | ||
| WO2022095801A1 (zh) | 靶向lir1的抗体及其用途 |